GATOR1 complex: the common genetic actor in focal epilepsies
Open Access
- 19 May 2016
- journal article
- review article
- Published by BMJ in Journal of Medical Genetics
- Vol. 53 (8) , 503-510
Abstract
The mammalian or mechanistic target of rapamycin (mTOR) signalling pathway has multiple roles in regulating physiology of the whole body and, particularly, the brain. Deregulation of mTOR signalling has been associated to various neurological conditions, including epilepsy. Mutations in genes encoding components of Gap Activity TOward Rags 1 (GATOR1) (DEPDC5, NPRL2 and NPRL3), a complex involved in the inhibition of the mTOR complex 1 (mTORC1), have been recently implicated in the pathogenesis of a wide spectrum of focal epilepsies (FEs), both lesional and non-lesional. The involvement of DEPDC5, NPRL2 and NRPL3 in about 10% of FEs is in contrast to the concept that specific seizure semiology points to the main involvement of a distinct brain area. The hypothesised pathogenic mechanism underlying epilepsy is the loss of the inhibitory function of GATOR1 towards mTORC1. The identification of the correct therapeutic strategy in patients with FE is challenging, especially in those with refractory epilepsy and/or malformations of cortical development (MCDs). In such cases, surgical excision of the epileptogenic zone is a curative option, although the long-term outcome is still undefined. The GATOR1/mTOR signalling represents a promising therapeutic target in FEs due to mutations in mTOR pathway genes, as in tuberous sclerosis complex, another MCD-associated epilepsy caused by mTOR signalling hyperactivation.Keywords
Funding Information
- Fondazione Telethon (GGP13200)
This publication has 70 references indexed in Scilit:
- mTOR signaling and its roles in normal and abnormal brain developmentFrontiers in Molecular Neuroscience, 2014
- Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivationFrontiers in Molecular Neuroscience, 2014
- A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trialsExpert Review of Neurotherapeutics, 2013
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1Science, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Deconvoluting mTOR biologyCell Cycle, 2012
- Role of mTOR in physiology and pathology of the nervous systemBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampusProceedings of the National Academy of Sciences, 2001
- Phosphatidic Acid-Mediated Mitogenic Activation of mTOR SignalingScience, 2001